×
S&P 500   3,911.74
DOW   31,500.68
QQQ   294.61
S&P 500   3,911.74
DOW   31,500.68
QQQ   294.61
S&P 500   3,911.74
DOW   31,500.68
QQQ   294.61
S&P 500   3,911.74
DOW   31,500.68
QQQ   294.61
NASDAQ:SABS

SAB Biotherapeutics Stock Forecast, Price & News

1.50
+0.27 (+21.95%)
(As of 06/24/2022 04:00 PM ET)
Add
Compare
Today's Range
1.27
1.63
50-Day Range
1.11
2.76
52-Week Range
1.11
12.90
Volume
146,700 shs
Average Volume
53,642 shs
Market Capitalization
$64.44 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
17.00
30 days | 90 days | 365 days | Advanced Chart

Receive SABS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for SAB Biotherapeutics and its competitors with MarketBeat's FREE daily newsletter.

SABS Stock Forecast (MarketRank)

Overall MarketRank

1.83 out of 5 stars

Medical Sector

743rd out of 1,411 stocks

Biological Products, Except Diagnostic Industry

121st out of 215 stocks

Analyst Opinion: 3.5Community Rank: 4.0Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -
SAB Biotherapeutics logo

About SAB Biotherapeutics (NASDAQ:SABS)

SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies based on human antibodies. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at specific diseases, including infectious diseases comprising COVID-19 and influenza, immune and autoimmune disorders, such as type 1 diabetes, organ transplantation, and cancer. The company uses its DiversitAb immunotherapy platform to produce fully-human polyclonal antibodies without the need for human donors. Its lead product candidates include SAB-185, a fully-human polyclonal antibody therapeutic candidate that is in Phase III clinical trial for the treatment of COVID-19; and SAB-176, a fully-human polyclonal antibody therapeutic candidate that is in development to treat or prevent severe influenza. The company's pre-clinical product candidates in development for autoimmune diseases include SAB-142 for type 1 diabetes and organ transplant induction/rejection. The company was founded in 2014 and is based in Sioux Falls, South Dakota.

SABS Stock News Headlines

SAB Biotherapeutics GAAP EPS of $0.02
See More Headlines

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:SABS
Fax
N/A
Employees
139
Year Founded
N/A

Company Calendar

Today
6/26/2022
Next Earnings (Estimated)
8/11/2022
Fiscal Year End
12/31/2022

Price Target and Rating

Average Stock Price Forecast
17.00
High Stock Price Forecast
23.00
Low Stock Price Forecast
7.00
Forecasted Upside/Downside
+1,033.3%
Consensus Rating
Buy
Rating Score (0-4)
3
Research Coverage
3 Analysts

Profitability

Net Income
$-17.15 million
Pretax Margin
-31.35%

Debt

Sales & Book Value

Annual Sales
$60.88 million
Book Value
0.89 per share

Miscellaneous

Free Float
24,918,000
Market Cap
$64.44 million
Optionable
Not Optionable
Beta
0.59














SAB Biotherapeutics Frequently Asked Questions

Should I buy or sell SAB Biotherapeutics stock right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for SAB Biotherapeutics in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" SAB Biotherapeutics stock.
View analyst ratings for SAB Biotherapeutics
or view top-rated stocks.

What is SAB Biotherapeutics' stock price forecast for 2022?

3 brokerages have issued 12 month target prices for SAB Biotherapeutics' stock. Their SABS stock forecasts range from 7.00 to 23.00. On average, they predict SAB Biotherapeutics' share price to reach 17.00 in the next year. This suggests a possible upside of 1,033.3% from the stock's current price.
View analysts' price targets for SAB Biotherapeutics
or view top-rated stocks among Wall Street analysts.

How has SAB Biotherapeutics' stock performed in 2022?

SAB Biotherapeutics' stock was trading at 7.81 on January 1st, 2022. Since then, SABS stock has decreased by 80.8% and is now trading at 1.50.
View the best growth stocks for 2022 here
.

When is SAB Biotherapeutics' next earnings date?

SAB Biotherapeutics is scheduled to release its next quarterly earnings announcement on Thursday, August 11th 2022.
View our earnings forecast for SAB Biotherapeutics
.

Who are SAB Biotherapeutics' key executives?

SAB Biotherapeutics' management team includes the following people:
  • Mr. Samuel J. Reich, Exec. Chairman (Age 47, Pay $212.58k)
  • Dr. Eddie Joe Sullivan Ph.D., Co-Founder, Pres, CEO & Director (Age 56, Pay $526.82k)
  • Ms. Christine E. Hamilton M.B.A., Co-Founder & Independent Director (Age 66, Pay $25k)
  • Dr. Edward D. Hamilton D.V.M., Co-Founder & Board Observer
  • Mr. Russell P. Beyer C.M.A., Chief Financial Officer (Age 67)
  • Dr. Christoph Bausch Ph.D., Chief Operating Officer (Age 51)
  • Dr. Carlos N. Carillo Ph.D., Sr. VP of Regulatory Affairs

What is SAB Biotherapeutics' stock symbol?

SAB Biotherapeutics trades on the NASDAQ under the ticker symbol "SABS."

Who are SAB Biotherapeutics' major shareholders?

SAB Biotherapeutics' stock is owned by a number of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (1.68%), State Street Corp (0.10%) and Qube Research & Technologies Ltd (0.06%).

Which institutional investors are buying SAB Biotherapeutics stock?

SABS stock was bought by a variety of institutional investors in the last quarter, including Vanguard Group Inc., State Street Corp, and Qube Research & Technologies Ltd.

How do I buy shares of SAB Biotherapeutics?

Shares of SABS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is SAB Biotherapeutics' stock price today?

One share of SABS stock can currently be purchased for approximately 1.50.

How much money does SAB Biotherapeutics make?

SAB Biotherapeutics (NASDAQ:SABS) has a market capitalization of $64.44 million and generates $60.88 million in revenue each year.

How many employees does SAB Biotherapeutics have?

SAB Biotherapeutics employs 139 workers across the globe.

How can I contact SAB Biotherapeutics?

SAB Biotherapeutics' mailing address is 300 W. 41ST STREET SUITE 202, MIAMI BEACH FL, 33140. The official website for SAB Biotherapeutics is www.bigcypressaccorp.com. The company can be reached via phone at 305-204-3338 or via email at [email protected].

This page (NASDAQ:SABS) was last updated on 6/26/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.